Deals in Phama / Biotech Pharma and Biotech Deals Boom – Highest Value Since 2009
Shopping spree in the pharma and biotech branch: The global deal value for Pharma, Medical & Biotech has reached a new high since its peak in 2009. The first quarter of 2014 saw deals valued at US $ 55.7 billion - nearly four times above last year’s US $ 14.2 billion.
Good news come also from Europe, where the US $ 8.1 billion-worth of deals is the third highest value for an opening quarter already on record, market analysts Mergermarket state. This volume is a hefty 44.6% above the first quarter of 2013 (US $ 5.6 billion) and the highest since 2010’s opening quarter (US $ 37.3 billion).
The US saw a busy week of mega-deals: The US $ 24.2 billion acquisition of Forest Laboratories by Actavis on Tuesday propelled the opening quarter’s deal value over thirteen times above the first three months of the previous year toa total of US $ 45.9 billion (from US $ 3.5 billion). As a result, quarter 2014 is already the highest values opening quarter since the peak in early 2009 (US $ 160.5 billion for the first quarter).